Hillsdale Investment Management Inc. Increases Stake in Hims & Hers Health, Inc. $HIMS

Hillsdale Investment Management Inc. boosted its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 13.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 145,810 shares of the company’s stock after acquiring an additional 17,810 shares during the period. Hillsdale Investment Management Inc.’s holdings in Hims & Hers Health were worth $7,269,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HIMS. Cerity Partners LLC bought a new stake in shares of Hims & Hers Health in the first quarter valued at approximately $325,000. CWM LLC boosted its holdings in Hims & Hers Health by 38.0% in the 1st quarter. CWM LLC now owns 9,556 shares of the company’s stock worth $282,000 after buying an additional 2,633 shares during the period. Victory Capital Management Inc. boosted its holdings in Hims & Hers Health by 173.9% in the 1st quarter. Victory Capital Management Inc. now owns 144,006 shares of the company’s stock worth $4,255,000 after buying an additional 91,427 shares during the period. Private Advisor Group LLC grew its stake in Hims & Hers Health by 243.9% in the 1st quarter. Private Advisor Group LLC now owns 44,375 shares of the company’s stock valued at $1,311,000 after buying an additional 31,471 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Hims & Hers Health in the 1st quarter valued at approximately $1,026,000. Institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. KeyCorp initiated coverage on Hims & Hers Health in a report on Tuesday, October 21st. They set a “sector weight” rating for the company. Zacks Research cut Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Bank of America increased their price target on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a report on Tuesday, November 4th. Finally, Truist Financial reduced their price objective on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research note on Monday, August 18th. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $45.27.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $33.64 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. Hims & Hers Health, Inc. has a 12-month low of $21.36 and a 12-month high of $72.98. The company has a market cap of $7.66 billion, a PE ratio of 62.30, a price-to-earnings-growth ratio of 7.13 and a beta of 2.20. The stock has a 50-day moving average price of $49.52 and a 200-day moving average price of $51.19.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The company had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business’s revenue was up 49.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.32 earnings per share. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its Board of Directors has authorized a share buyback program on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to purchase up to 3% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In related news, insider Michael Chi sold 900 shares of the firm’s stock in a transaction dated Friday, October 10th. The stock was sold at an average price of $58.25, for a total transaction of $52,425.00. Following the transaction, the insider directly owned 291,439 shares of the company’s stock, valued at approximately $16,976,321.75. This trade represents a 0.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 2,637 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $42.53, for a total value of $112,151.61. Following the completion of the sale, the insider directly owned 155,856 shares of the company’s stock, valued at approximately $6,628,555.68. This represents a 1.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 630,583 shares of company stock valued at $33,544,943 over the last 90 days. Insiders own 13.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.